Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zomacton vs Genotropin in Children With Idiopathic Growth Hormone Deficiency
NCT00884000Phase 3Completed
- Sponsor
- Ferring Pharmaceuticals
- Start
- Jan 2010
- Primary completion
- Jun 2012
- Modality
- Hormone, rProtein (Recombinant Protein), Biologic
- Countries
- 7
01
Overview
Phase 3, randomised, open-label trial of somatropin in growth hormone deficiency (GHD) (2 arms), sponsored by Ferring Pharmaceuticals. Primary endpoint: Height Velocity at 12 months. Started Jan 2010; status: completed.
02
Drugs
somatropin
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NCT00884000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00884000.